Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors

Summary

This is a single-arm phase II study of twenty-one subjects with mucinous adenocarcinoma of the colon, rectum, or appendix with prior systemic therapy with a fluoropyrimidine, oxaliplatin, and irinotecan. Treatment will consist of nivolumab 480mg every 4 weeks and ipilimumab 1mg/kg every 8 weeks until disease progression, unacceptable toxicity, or 2 years of therapy.

Timeline

Start

2019-02-15

Primary completion

2021-03-06

Completion

2021-03-06

Outcome

Outcome not reported

Stopped (Enrollment): “Terminated due to slow enrollment and lack of efficacy”

Drugs

Indications